Difference between revisions of "Bicalutamide (Casodex)"
Jump to navigation
Jump to search
m (→References) |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.<ref name="insert">[http://www1.astrazeneca-us.com/pi/casodex.pdf Bicalutamide (Casodex) package insert]</ref><ref>[[Media:Bicalutamide.pdf | Bicalutamide (Casodex) package insert (locally hosted backup)]]</ref> | Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.<ref name="insert">[http://www1.astrazeneca-us.com/pi/casodex.pdf Bicalutamide (Casodex) package insert]</ref><ref>[[Media:Bicalutamide.pdf | Bicalutamide (Casodex) package insert (locally hosted backup)]]</ref> | ||
| Line 19: | Line 17: | ||
*10/4/1995: Initial FDA approval | *10/4/1995: Initial FDA approval | ||
*5/11/2005: Indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage D2 metastatic [[Prostate cancer | carcinoma of the prostate]]. | *5/11/2005: Indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage D2 metastatic [[Prostate cancer | carcinoma of the prostate]]. | ||
| + | |||
| + | ==Also known as== | ||
| + | Cosudex, Calutide, or Kalumid. | ||
==References== | ==References== | ||
Revision as of 23:34, 16 March 2017
General information
Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, MedscapeUpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Bicalutamide (Casodex) package insert pages 20-24[1]
- Bicalutamide (Casodex) patient drug information (Chemocare)[3]
- Bicalutamide (Casodex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 10/4/1995: Initial FDA approval
- 5/11/2005: Indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.
Also known as
Cosudex, Calutide, or Kalumid.